Artemisinin Resistance Is Spreading Across East Africa: What It Actually Means for Your Malaria Pills
A July 2026 study in The Lancet Infectious Diseases mapped artemisinin partial resistance across Africa using 185,099 parasite samples from 47 countries, and found it is now firmly established across most of Uganda and Rwanda and along the Ethiopia-Eritrea-Sudan border rather than confined to isolated pockets. In Rwanda's Northern Province, predicted prevalence rose from under 1 percent in 2012 to 62 percent in 2024. Here is the distinction that matters for travelers: artemisinin is a treatment drug, not a prevention drug. The atovaquone-proguanil our providers prescribe for prophylaxis works by a different mechanism and is unaffected by these mutations. Resistance raises the stakes on not getting malaria in the first place. Start your free destination check on Wandr.
Researchers at Imperial College London published the first high-resolution maps of artemisinin partial resistance in Africa this month, in The Lancet Infectious Diseases. Drawing on 185,099 parasite samples across 47 African countries, they found resistance to the central drug in frontline malaria treatment is no longer confined to isolated pockets. It is now firmly established across most of Uganda and Rwanda and along the Ethiopia-Eritrea-Sudan border.
Our providers prescribe malaria prophylaxis for East Africa every week, so we can answer the obvious question immediately: no, this does not mean your malaria pills stopped working.
The numbers behind the headline are real. In Rwanda's Northern Province, predicted prevalence of the resistance markers rose from under 1 percent in 2012 to 62 percent in 2024.
But the distinction between treatment drugs and prevention drugs is the whole story here, and it is worth ten minutes of your attention before a safari or a gorilla-trekking trip. The reassuring part is true. So is the part that should change how carefully you take your tablets.
The one distinction that resolves most of the confusion
Artemisinin is a treatment drug. Atovaquone-proguanil, which most travelers know as Malarone, is what our providers prescribe for prevention.
Artemisinin-based combination therapies, abbreviated ACTs, are what a clinic in Kampala or Kigali gives a patient who already has malaria. They pair fast-acting artemisinin with a longer-lasting partner drug. They are the backbone of malaria treatment across sub-Saharan Africa, and they are what the Lancet study is about.
Atovaquone-proguanil taken as prophylaxis is a different drug attacking the parasite through a different mechanism. The k13 gene mutations that drive artemisinin partial resistance do not confer resistance to it. Your prophylaxis is not weakened by this finding.
That is the reassuring half. Here is the half that should change your behaviour.
Why this raises the stakes on prevention
Resistance findings do not make prophylaxis less effective. They make failing at prophylaxis more expensive.
The chain runs like this. You skip doses because Malarone upset your stomach, or you stop the day you fly home instead of finishing the full seven days afterward, or you decide a five-day trip is too short to bother. You catch falciparum malaria. Now the drugs available to treat you are operating under more pressure than they were ten years ago, in a region where the resistance markers are the most prevalent on the continent.
WHO's World Malaria Report 2025 confirmed or suspected artemisinin partial resistance in at least eight African countries. That is a surveillance picture that has been deteriorating for several years.
Prevention was always the better plan. This narrows the margin for error on executing it.
What partial resistance does and does not mean
The word "partial" carries real weight, and skipping it produces the wrong conclusion.
Partial resistance means the parasite clears more slowly after treatment than it should. It does not mean the drug has failed. WHO's position is that patients infected with artemisinin partial resistant parasites are still nearly always cured by an ACT, provided the partner drug in that combination remains highly effective in the local area.
The concern the researchers raise is sequencing. In Southeast Asia, artemisinin partial resistance appeared first, resistance to the partner drugs followed, and widespread ACT treatment failure followed that. The Lancet team explicitly noted that the East African pattern mirrors those early warning signs, and that risk concentrates where k13 mutations and markers of reduced partner-drug susceptibility occur together.
Dr Robert Verity of Imperial College London, who led the analysis, framed it plainly: artemisinin-based drugs underpin malaria treatment across sub-Saharan Africa, and the findings are a warning that they cannot be taken for granted.
There is also a detail in the study that matters specifically for travelers. Recrudescence, meaning the infection reappearing after apparently successful treatment, is more likely in patients with high initial parasite loads, younger patients, pregnant women, and people with little or no background immunity. That last category is you. An American traveler has no acquired immunity to falciparum malaria, which is precisely why travelers get sicker faster than local residents with the same infection.
What this means for East Africa itineraries
The affected geography maps directly onto some of the most popular trips on the continent.
Most of Uganda and Rwanda now show established resistance markers. That covers gorilla trekking in Bwindi Impenetrable Forest and Volcanoes National Park, the Ugandan safari circuit through Queen Elizabeth and Murchison Falls, and Kigali as a gateway. The Ethiopia-Eritrea-Sudan border corridor is the other established zone, relevant to travel through northern Ethiopia.
Malaria transmission itself is the thing that puts you at risk, and that has not changed. Tanzania, Kenya, Uganda and Rwanda remain destinations where falciparum malaria is the dominant species and where prophylaxis is standard for travelers. CDC also maintains an active notice for malaria in Ethiopia, with increased cases reported from all 14 regions.
WHO's global numbers give the scale. An estimated 282 million malaria cases and 610,000 deaths worldwide in 2024, with the African Region carrying 94 percent of cases and 95 percent of deaths. Five countries, including Uganda, Ethiopia and the Democratic Republic of the Congo, account for more than half of global cases.
If East Africa is on your itinerary, our complete guide to malaria prevention for travelers covers the full prevention picture, and our breakdown of falciparum malaria and Malarone covers why species matters for how quickly a fever becomes an emergency.
Getting prophylaxis right, specifically
The advice here is unglamorous and it is where all the value sits.
Start on time. Atovaquone-proguanil is started one to two days before you enter the malaria zone. Not the morning of your flight, and not once you notice mosquitoes.
Take it with food. Absorption improves substantially with a meal or a fatty snack, and taking it on an empty stomach is the most common reason travelers get nausea and then quietly stop.
Finish the seven days after you leave. This is the step most often abandoned. Prophylaxis works against the parasite stage that emerges from the liver after the bite, so stopping when you board the plane home leaves the window open. A week of tablets after you land is not optional padding.
Do not skip bite prevention because you are on tablets. Prophylaxis is one layer. Repellent with 20 to 30 percent DEET or 20 percent picaridin, long sleeves at dusk and dawn when Anopheles mosquitoes feed, and a treated bed net or screened room are the others. Malarone is highly effective, not absolute.
You can get atovaquone-proguanil through Wandr without a travel clinic visit. Our providers review your destination, trip dates, medical history and current medications, and confirm whether it is the right choice for you. Start your free destination check and we will tell you what your route needs.
The fever rule
This is the part to remember if you remember nothing else.
Any fever after travel to a malaria zone is a medical emergency until malaria has been excluded. Falciparum malaria can go from fever to severe illness within 24 hours. Symptoms usually appear within the first month after exposure but can emerge up to a year later.
Go to an emergency department. Say the words: "I traveled to a malaria area, here are the dates." That sentence changes the entire workup, and it is the single most useful thing you can do for yourself. Ask for a blood smear or a rapid diagnostic test.
Do this even if you took every dose perfectly. Prophylaxis substantially reduces risk. It does not eliminate it, and a traveler with no background immunity has very little time to spare if the test comes back positive.
The honest summary
The Lancet mapping study is a serious public health finding. Artemisinin partial resistance is more widespread and more established in East Africa than the previous picture suggested, and the trajectory resembles what preceded treatment failure in Southeast Asia.
For a traveler, it does not change which prophylaxis to take. It changes how seriously to take it. Your Malarone still works. The consequences of not finishing it are worse than they were.
Start on time, take it with food, finish the seven days after you leave, use repellent anyway, and treat any post-travel fever as urgent. Start your destination check on Wandr and our providers will build the plan around your actual route.
Related reading
- Malaria Prevention for Travelers: The Complete Guide
- Falciparum Malaria and Malarone: What Every Traveler to a Malaria Zone Should Know
- Malarone dosage and side effects
- Get atovaquone-proguanil through Wandr
Sources
- Young NW, Meier-Scherling CPG, Cuomo-Dannenburg G, et al. Mapping the prevalence of molecular markers of Plasmodium falciparum artemisinin partial resistance in Africa: a systematic review and spatiotemporal modelling study. The Lancet Infectious Diseases, 2026
- Imperial College London, Artemisinin resistance is rising in East Africa, leaving anti-malarials at risk of failure, 10 July 2026
- WHO, World Malaria Report 2025
- WHO, Questions and answers on artemisinin partial resistance
- CDC Travel Health Notices, Malaria in Ethiopia
This article is for general education and does not replace an individual clinical assessment. Wandr Health providers are licensed clinicians who can evaluate your specific itinerary and history.
Frequently Asked Questions
No. Artemisinin and atovaquone-proguanil, sold as Malarone, are different drugs that attack the parasite by different mechanisms, and the k13 mutations driving artemisinin partial resistance do not confer resistance to atovaquone-proguanil. Artemisinin-based combination therapies are treatment for an established infection, usually given in malaria-endemic countries. Atovaquone-proguanil taken as prophylaxis is prevention. The Lancet findings are about the former.
Because it changes the consequences of prophylaxis failure. If you skip doses, cut your regimen short, or travel without prophylaxis and then catch falciparum malaria in Uganda or Rwanda, the drugs used to treat you are under more pressure than they were a decade ago. WHO's World Malaria Report 2025 confirmed or suspected artemisinin partial resistance in at least eight African countries. Prevention has always been the better plan. This makes the margin narrower.
Partial resistance means the parasite clears more slowly than it should after treatment, not that the drug has stopped working. WHO's position is that patients infected with artemisinin partial resistant parasites are still nearly always cured by an artemisinin-based combination therapy, provided the partner drug in the combination remains highly effective in that area. The concern researchers raise is what happens if resistance to the partner drugs develops on top of it, which is the sequence that preceded widespread treatment failure in Southeast Asia.
The study found artemisinin partial resistance firmly established across most of Uganda and Rwanda and along the Ethiopia-Eritrea-Sudan border. That covers gorilla-trekking itineraries in southwest Uganda and Rwanda, Ugandan safari circuits, and travel through the Ethiopian highlands and lowlands. Tanzania and Kenya safari routes remain high-priority malaria destinations regardless of the resistance picture, because falciparum transmission there is what puts you at risk in the first place.
For most travelers, no. Atovaquone-proguanil remains an appropriate first-line prophylaxis choice for East Africa, and our providers prescribe it based on your destination, trip length, medical history and current medications rather than on the artemisinin picture. What should change is your adherence. Start on schedule, take every dose with food, and finish the full seven days after you leave the malaria zone.
Treat it as a medical emergency until malaria is excluded. Falciparum malaria can progress from fever to severe illness within 24 hours, and the incubation period means symptoms can appear up to a year after exposure, most often within the first month. Go to an emergency department, state clearly that you traveled to a malaria zone and give the dates. Prophylaxis reduces risk substantially but does not eliminate it, so a fever after travel needs a blood smear or rapid test even if you took every dose.
WHO's World Malaria Report 2025 estimated 282 million malaria cases and 610,000 deaths worldwide in 2024, a slight increase over 2023. The African Region accounts for 94 percent of cases and 95 percent of deaths, and five countries including Uganda, Ethiopia and the Democratic Republic of the Congo make up more than half of global cases. Global malaria funding in 2024 was 3.9 billion dollars against a 9.3 billion dollar target, which is part of why resistance is spreading faster than the response.
The Wandr Team is the editorial group at Wandr Health; every article is reviewed by a licensed clinician before publication.